|
Tuvusertib Clinical Trials
4 actively recruiting trials across 3 locations
Also known as: ATR Kinase Inhibitor M1774, M 1774, M-1774, M1774
Pipeline
Phase 1: 2Phase 2: 1Phase 1/2: 1
Top Sponsors
- National Cancer Institute (NCI)3
- Grupo Español de Investigación en Neurooncología1
Indications
- Cancer4
- Metastatic Malignant Solid Neoplasm2
- Advanced Malignant Solid Neoplasm2
- Recurrent Ovarian Low Grade Endometrioid Adenocarcinoma1
- Recurrent Ovarian High Grade Serous Adenocarcinoma1
Other1 trial
Irvine, California1 trial
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Phase 1/2
Augusta, Georgia1 trial
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Augusta University Medical Center
Phase 1
Bethesda, Maryland1 trial
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
National Cancer Institute Developmental Therapeutics Clinic
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.